Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 35 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature.
Gamie Z, Krippner-Heidenreich A, Gerrand C, Rankin KS
Front Mol Biosci, 11:1384795, 02 Sep 2024
Cited by: 0 articles | PMID: 39286782 | PMCID: PMC11402684
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia.
Barneh F, Koedijk JB, Wijnen NE, Meulendijks T, Ashtiani M, Dunnebach E, Dautzenberg N, Cornel AM, Krippner-Heidenreich A, Klein K, Zwaan MC, Kuball J, Nierkens S, Cloos J, Kaspers GJL, Heidenreich O
Haematologica, 08 Aug 2024
Cited by: 0 articles | PMID: 39113654
Add to export list
Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V, Meringa A, Dunnebach E, van Velzen A, Moreira AV, Stam RW, Kotecha RS, Krippner-Heidenreich A, Heidenreich OT, Plantinga M, Cornel A, Sebestyen Z, Kuball J, van Til NP, Nierkens S
J Immunother Cancer, 12(4):e008174, 05 Apr 2024
Cited by: 0 articles | PMID: 38580329 | PMCID: PMC11002379
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia
Barneh F, Koedijk JB, Wijnen NE, Meulendijks T, Ashtiani M, Dunnebach E, Dautzenberg N, Cornel AM, Krippner-Heidenreich A, Klein K, Zwaan CM, Kuball J, Nierkens S, Cloos J, Kaspers GJ, Heidenreich O
bioRxiv, 22 Apr 2024
Cited by: 0 articles | PPR: PPR841193
Add to export list Preprint
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.
Cornel AM, van der Sman L, van Dinter JT, Arrabito M, Dunnebach E, van Hoesel M, Kluiver TA, Lopes AP, Dautzenberg NMM, Dekker L, van Rijn JM, van den Beemt DAMH, Buhl JL, du Chatinier A, Barneh F, Lu Y, Lo Nigro L, Krippner-Heidenreich A, Sebestyén Z, [...] Nierkens S
J Immunother Cancer, 12(3):e007538, 21 Mar 2024
Cited by: 0 articles | PMID: 38519054 | PMCID: PMC10961533
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
Barajas JM, Rasouli M, Umeda M, Hiltenbrand R, Abdelhamed S, Mohnani R, Arthur B, Westover T, Thomas ME, Ashtiani M, Janke LJ, Xu B, Chang TC, Rosikiewicz W, Xiong E, Rolle C, Low J, Krishan R, Song G, [...] Klco JM
Blood, 143(7):619-630, 01 Feb 2024
Cited by: 13 articles | PMID: 37890156 | PMCID: PMC10873536
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth.
Kellaway SG, Potluri S, Keane P, Blair HJ, Ames L, Worker A, Chin PS, Ptasinska A, Derevyanko PK, Adamo A, Coleman DJL, Khan N, Assi SA, Krippner-Heidenreich A, Raghavan M, Cockerill PN, Heidenreich O, Bonifer C
Nat Commun, 15(1):1359, 14 Feb 2024
Cited by: 6 articles | PMID: 38355578 | PMCID: PMC10867020
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia
Arza-Apalategi S, Heuts BMH, Bergevoet SM, Meering R, Gilissen D, Jansen PWTC, Krippner-Heidenreich A, Valk PJM, Vermeulen M, Heidenreich O, Haferlach T, Jansen JH, Martens JHA, van der Reijden BA
bioRxiv, 09 Nov 2023
Cited by: 0 articles | PPR: PPR756938
Add to export list Preprint
P444: SINGLE CELL RNASEQ UNCOVERING THE ROLE OF A LEUKEMIC DRIVER GENE FUSION CBFΒ::MYH11 IN THE LEUKEMIC–NICHE SIGNALING
Derevyanko P, V Dolgikh A, Ashtiani M, Krippner-Heidenreich A, Nelson R, Bushweller J, Barbitoff Y, V Predeus A, Heidenreich O
Hemasphere, 7(suppl ), 01 Aug 2023
Cited by: 0 articles | PMCID: PMC10429320
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
Wijnen N, Barneh F, Meulendijks T, Klein K, Duddebach E, Cornel A, Dautzenberg N, Ashtiani M, Krippner-Heidenreich A, Nierkens S, Heidenreich O, Kaspers G
Hemasphere, 7(suppl ), 01 Aug 2023
Cited by: 0 articles | PMCID: PMC10429302
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O
Hemasphere, 7(8):e935, 27 Jul 2023
Cited by: 8 articles | PMID: 37520776 | PMCID: PMC10378738
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles.
Swart LE, Fens MHAM, van Oort A, Waranecki P, Mata Casimiro LD, Tuk D, Hendriksen M, van den Brink L, Schweighart E, Seinen C, Nelson R, Krippner-Heidenreich A, O'Toole T, Schiffelers RM, Kooijmans S, Heidenreich O
Pharmaceutics, 15(6):1603, 27 May 2023
Cited by: 0 articles | PMID: 37376052 | PMCID: PMC10304323
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth
Kellaway SG, Potluri S, Keane P, Blair HJ, Chin PS, Ptasinska A, Worker A, Ames L, Adamo A, Coleman DJ, Khan N, Assi SA, Krippner-Heidenreich A, Raghavan M, Cockerill PN, Heidenreich O, Bonifer C
bioRxiv, 12 Mar 2023
Cited by: 0 articles | PPR: PPR629320
Add to export list Preprint
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW
Haematologica, 106(4):1056-1066, 01 Apr 2021
Cited by: 20 articles | PMID: 32139432 | PMCID: PMC8018112
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression.
Urbano PCM, Aguirre-Gamboa R, Ashikov A, van Heeswijk B, Krippner-Heidenreich A, Tijssen H, Li Y, Azevedo VF, Smits LJT, Hoentjen F, Joosten I, Koenen HJPM
J Allergy Clin Immunol, 142(2):517-529, 14 Dec 2017
Cited by: 25 articles | PMID: 29248493
Add to export list
TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.
Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS
Cancer Lett, 409:66-80, 06 Sep 2017
Cited by: 20 articles | PMID: 28888998
Add to export list Review
Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2.
Maney NJ, Reynolds G, Krippner-Heidenreich A, Hilkens CMU
J Immunol, 193(10):4914-4923, 06 Oct 2014
Cited by: 40 articles | PMID: 25288570 | PMCID: PMC4896387
Add to export list Free full text in Europe PMC
CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.
Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E
Cell Death Dis, 4:e782, 29 Aug 2013
Cited by: 22 articles | PMID: 23990022 | PMCID: PMC3763465
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.
Gardner A, Fisher AJ, Richter C, Johnson GE, Moisey EJ, Brodlie M, Ward C, Krippner-Heidenreich A, Mann DA, Borthwick LA
Am J Pathol, 180(6):2293-2308, 21 Apr 2012
Cited by: 21 articles | PMID: 22525462 | PMCID: PMC3366074
Add to export list Free full text in Europe PMC
Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts.
Hügle T, O'Reilly S, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M, Krippner-Heidenreich A, van Laar JM
Arthritis Rheum, 65(2):481-491, 01 Feb 2013
Cited by: 43 articles | PMID: 23045159 | PMCID: PMC6588536
Add to export list Free full text in Europe PMC
The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.
Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M
PLoS One, 7(8):e42526, 03 Aug 2012
Cited by: 10 articles | PMID: 22916132 | PMCID: PMC3420232
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.
Richter C, Messerschmidt S, Holeiter G, Tepperink J, Osswald S, Zappe A, Branschädel M, Boschert V, Mann DA, Scheurich P, Krippner-Heidenreich A
Mol Cell Biol, 32(13):2515-2529, 30 Apr 2012
Cited by: 36 articles | PMID: 22547679 | PMCID: PMC3434479
Add to export list Free full text in Europe PMC
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.
Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K, Gerspach J
Cell Death Dis, 1:e68, 26 Aug 2010
Cited by: 39 articles | PMID: 21364672 | PMCID: PMC3032523
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness.
Branschädel M, Aird A, Zappe A, Tietz C, Krippner-Heidenreich A, Scheurich P
Cell Signal, 22(3):404-414, 01 Mar 2010
Cited by: 17 articles | PMID: 19879354
Add to export list
Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors.
Gerken M, Krippner-Heidenreich A, Steinert S, Willi S, Neugart F, Zappe A, Wrachtrup J, Tietz C, Scheurich P
Biochim Biophys Acta, 1798(6):1081-1089, 23 Feb 2010
Cited by: 6 articles | PMID: 20188063
Add to export list

1-25 of 35 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia.

Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.

Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth.

The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

P444: SINGLE CELL RNASEQ UNCOVERING THE ROLE OF A LEUKEMIC DRIVER GENE FUSION CBFΒ::MYH11 IN THE LEUKEMIC–NICHE SIGNALING

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES

The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.

Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles.

Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth

Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.

TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression.

TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.

Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2.

CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.

The critical role of TAK1 in accentuated epithelial to mesenchymal transition in obliterative bronchiolitis after lung transplantation.

Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts.

The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.

The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.

Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness.

Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors.

Partnerships & funding